

Zenicor signs their second major agreement in Finnish primary care

Stockholm, July 6th 2018

Today Zenicor Medical Systems AB announces that they have signed a commercial agreement with Tampere Heart Hospital (Tampere Sydänsairaala) in Finland. The agreement is a result of yet another successful project in Finland which was carried out the first half of 2018. Tampere Heart Hospital will provide the Zenicor-ECG service to the primary care in central Finland and Zenicor receives revenue per patient undergoing investigation.

– Finland is at the forefront of improving the care pathway and we are glad that we've earned the trust to implement our system for early diagnosis to even more healthcare centers in the country. The agreement is at the same time an acknowledgement that the projects we implement result in long-term commercial agreements." says Zenicor's CEO Mats Palerius.

Zenicor's investigations for early diagnosis of arrhythmias in a new care pathway enables early preventive treatment. Zenicor-ECG supports the optimized care pathway and integrates with the clinical routines. Zenicor now has two agreements (Oulu Heart Center and Tampere Heart Hospital) for primary arrhythmia investigations in Finland, and together with these partners, Zenicor-ECG can offer more than half of Finland's healthcare centers this solution.

The new and improved care pathway implicates:

- Zenicor-ECG is directly handed out at the patient's primary care visit
- Reduced waiting times and increased accessibility for the patient
- Reduced need for referral to another healthcare provider
- Reduced paperwork when ECG can be interpreted remotely by specialists in cardiology

Kjell Nikus, Cardiologist at Tampere Heart Hospital and Professor of Cardiology at The University of Tampere comments:

–New methods for diagnosing atrial fibrillation are clearly needed. Zenicor allows for early diagnosis and there is a potential for savings in healthcare costs as anticoagulant -treatment can commence faster than with traditional diagnostics.*

– We have been working for a long time with established healthcare professionals internationally to create long-term improvements for healthcare providers and their patients. We will continue to work on spreading our solutions to more partners in Finland and additional countries in Europe, " says Mats Palerius.

Press release

About Tampere Heart Hospital

Tampere Heart Hospital is a full-service hospital specializing in cardiac care and is a limited company owned by Tampere University Hospital. The core of the hospital's activities has been built around the patient's care pathway. The Heart Hospital is responsible for special care of private and public cardiac patients in Birkaland and also produces services for other municipalities, healthcare districts and stakeholders in the healthcare industry. At the Heart Hospital there are almost 400 professionals who specialize in the treatment of heart diseases, of whom 60 are physicians. The multi-professional competence ensures a smooth, reliable and safe patient experience for the patient

About Zenicor and Thumb-ECG from Zenicor

Zenicor Medical Systems, founded in Sweden in 2002, is one of the leading medtech companies in Europe in the field of early diagnosis of arrhythmias and stroke prevention for healthcare. Zenicor has developed a unique system, Zenicor-ECG, for early detection and diagnosis of arrhythmias easily and cost-effectively. The efficiency of the solution has been documented in a number of studies and articles in internationally leading scientific journals. These studies have shown that Zenicor's ECG has a superior diagnostic ability, combined with cost-effectiveness and ease of use compared to traditional methods.

For more information, please contact:

Mats Palerius, CEO, Zenicor Medical Systems AB,

Phone: +46 70 561 55 64

E-mail: mats@zenicor.se

High resolution images of Zenicor ECG are available for downloading: <http://zenicor.se/pressmaterial>

This information is the type of information which Zenicor is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on June 6th 2018

